AFFILIATIONS
1 University of California, Los Angeles, Los Angeles, California, United States
2 University of California, Los Angeles, Los Angeles, California, United States
3 University of California, Los Angeles, Los Angeles, California, United States
4 University of California, Los Angeles, Los Angeles, California, United States
5 University of California, Los Angeles, Los Angeles, California, United States
6 University of California, Los Angeles, Los Angeles, California, United States
7 University of California, Los Angeles, Los Angeles, California, United States
8 University of California, Los Angeles, Los Angeles, California, United States
9 University of California, Los Angeles, Los Angeles, California, United States
10 University of California, Los Angeles, Los Angeles, California, United States
11 University of California, Los Angeles, Los Angeles, California, United States
12 University of California, Los Angeles, Los Angeles, California, United States
13 University of California, Los Angeles, Los Angeles, California, United States
14 University of California, Los Angeles, Los Angeles, California, United States
15 University of California, Los Angeles, Los Angeles, California, United States
16 University of California, Los Angeles, Los Angeles, California, United States
17 University of California, Los Angeles, Los Angeles, California, United States
18 University of California, Los Angeles, Los Angeles, California, United States
19 University of California, Los Angeles, Los Angeles, California, United States
20 University of California, Los Angeles, Los Angeles, California, United States
21 University of California, Los Angeles, Los Angeles, California, United States
22 University of California, Los Angeles, Los Angeles, California, United States
ABSTRACT
Introduction
Single input, CD19-directed CAR-T therapy has several indications but over half of patients relapse due mechanisms including antigen escape and lack of CAR-T cell persistence. To address this, autologous CAR-T cells with a bispecific anti-CD19/CD20 chimeric antigen receptor (CART19/20) were developed. Herein, we report 5-year follow up of a first-in-human phase 1 trial of CART19/20 for patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) (NCT04007029).
Methods
Eligibility criteria included age greater than or equal to 18 years old, ECOG of 1 or less, and R/R NHL after 2 to 3 prior lines of therapy, depending on the specific disease. CART19/20 cells were generated by lentiviral transduction of autologous naïve/memory T cells. The primary endpoint was safety, and secondary endpoints included response, progression free survival (PFS), overall survival (OS), and persistence of CART19/20.
Results
15 patients received CART19/20 cells, with disease distribution as follows: 6 DLBCL, 1 HGBCL, 4 FL, and 4 MCL. Twelve patients received a dose of 50x106 +/- 30% cells, and the other 3 received 200x106 +/- 30% cells. The median age was 60, with a median of 4 prior lines of therapy. Fourteen had stage IV disease and 1 had stage III disease. Most patients received bridging therapy. Grade 1 CRS was observed in 9 patients, and grade 2 CRS was observed in 1 patient. No ICANS or grade 3 or 4 CRS was seen. Median time to onset of CRS was 7 days. Tocilizumab was used in 2 out of 10 patients who experienced CRS; none of these patients received steroids. There were 12 serious adverse events, 2 dose limiting toxicities, and no deaths related to CART19/20. Objective response rate was 93% and 80% of patients had a complete response. At median follow-up of 59 months, median PFS was 37.5 months and median OS was not reached. Persistence of CART19/20 cells based on available measurements from date of infusion was on average greater than 17 months.
Conclusion
With 5 year follow up, CART19/20 demonstrated durable responses with an acceptable safety profile, providing longer-term support for this dual-targeted approach in patients with R/R NHL.